Infusion of the Substance P Analogue, DiMe-C7, into the Ventral Tegmental Area Induces Reinstatement of Cocaine-seeking Behaviour in Rats
Overview
Affiliations
Rationale: The mesocorticolimbic dopamine (DA) system is critically involved in mediating reinstatement of drug-seeking behaviour. Substance P (SP) is a neuropeptide that significantly interacts with the mesocorticolimbic system, therefore suggesting a possible role for the SP system in the mediation of relapse.
Objectives: This study examined the effects of injections of the SP analogue, DiMe-C7, into the ventral tegmental area (VTA) on reinstatement of cocaine-seeking behaviour, as well as on locomotor activity in rats. Additionally, this study examined whether these effects are DA-dependent.
Methods: Rats were trained to self-administer cocaine for 15 days followed by 15 days of extinction. Reinstatement of cocaine-seeking behaviour was then measured in response to bilateral intra-VTA microinjections of DiMe-C7 (0, 0.1, 0.5 and 2.5 microg). In a separate group of rats, locomotor activity was measured in response to intra-VTA injections of DiMe-C7 (0, 0.5, 1.5 and 3 microg). The effects of pre-treatment with DA receptor antagonists on DiMe-C7-induced reinstatement and locomotor activity were also examined. Animals were pre-treated with the D(1) and D(2) receptor antagonists, SCH23390 and haloperidol (0, 0.01 and 0.03 mg/kg, IP), respectively, prior to receiving intra-VTA injections of DiMe-C7 (0 and 2.5 microg).
Results: Infusion of DiMe-C7 into the VTA increased locomotor activity and induced reinstatement of cocaine-seeking behaviour. Both SCH23390 and haloperidol blocked intra-VTA DiMe-C7-induced locomotor activation. In addition, SCH23390 attenuated DiMe-C7-induced reinstatement of cocaine-seeking behaviour, while haloperidol had no effect.
Conclusions: These results suggest that interactions between SP and the mesocorticolimbic DA system may play a role in mediating reinstatement of cocaine-seeking behaviour and that the involvement of these interactions in reinstatement are dependent upon D(1) receptor mechanisms.
Neurokinin receptors in drug and alcohol addiction.
Schank J Brain Res. 2020; 1734:146729.
PMID: 32067964 PMC: 7138066. DOI: 10.1016/j.brainres.2020.146729.
Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics.
Ubaldi M, Cannella N, Ciccocioppo R Prog Brain Res. 2016; 224:251-84.
PMID: 26822362 PMC: 5098406. DOI: 10.1016/bs.pbr.2015.07.018.
The pharmacology of neurokinin receptors in addiction: prospects for therapy.
Sandweiss A, Vanderah T Subst Abuse Rehabil. 2015; 6:93-102.
PMID: 26379454 PMC: 4567173. DOI: 10.2147/SAR.S70350.
Stress-related neuropeptides and addictive behaviors: beyond the usual suspects.
Schank J, Ryabinin A, Giardino W, Ciccocioppo R, Heilig M Neuron. 2012; 76(1):192-208.
PMID: 23040815 PMC: 3495179. DOI: 10.1016/j.neuron.2012.09.026.
Brown Z, Kupferschmidt D, Erb S Psychopharmacology (Berl). 2012; 224(3):431-40.
PMID: 22707255 DOI: 10.1007/s00213-012-2772-3.